AgenciesAstraZeneca's COVID-19 shot did not increase the instances of rare blood clots with low platelets in people after the second dose, a study published in the Lancet medical journal showed on Wednesday.
The data found that the estimated rate of thrombosis with thrombocytopenia syndrome (TTS) after the second dose of the vaccine, Vaxzevria, was 2.3 per million in those inoculated, comparable to the typical rate seen in those who have not been vaccinated, said.
The same rate was 8.1 after the first dose, it added.
The data found that the estimated rate of thrombosis with thrombocytopenia syndrome (TTS) after the second dose of the vaccine, Vaxzevria, was 2.3 per million in those inoculated, comparable to the typical rate seen in those who have not been vaccinated, said.
The same rate was 8.1 after the first dose, it added.
Did you Know?
Stock score of Astrazeneca Pharma India Ltd moved down by 3 in 3 months on a 10-point scale.
View Latest Stock Report »Read More News on
Download The Economic Times News App to get Daily Market Updates & Live Business News.